ClinicalTrials.gg
RecruitingNCT07824258Updated Sep 24, 2026

Post-Vasectomy Pain Study

A Phase 1 interventional study of Acetaminophen and ibuprofen in Vasectomy, NSAIDs and Post-operative Care, sponsored by Columbia University. Recruiting at 2 sites in United States. Open to male participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-09-24.

Sponsored by Columbia University · Phase 1, Interventional, and Supportive care

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
Male
01

Study summary

This is a prospective four-armed unblinded randomized controlled trial to assess four different potential post-operative treatment options for men who undergo a vasectomy. The aims of this study are:

  • To determine whether the addition of nonsteroidal anti-inflammatory drugs (NSAIDs) to acetaminophen results in improved pain after vasectomy;
  • To determine whether the addition of opioid pain medication to acetaminophen and/or NSAIDs results in improved pain after vasectomy;
  • To determine whether the use of NSAIDs for post-operative pain management increases risk of hematoma after vasectomy.
Read the detailed description

The purpose of this study is to evaluate and compare commonly used post-vasectomy pain regimens. Eligible participants will be adult male patients who elect to undergo vasectomy with a urologist at Columbia University Medical Center with no history of kidney or liver disease, chronic pain conditions, or drug abuse. Prospectively enrolled participants will be randomized to one of four study arms, which will differ by post-operative pain regimens as follows:

  • Arm 1: 975 mg acetaminophen every 6 hours for the first 48 hours to a maximum of 7 days;
  • Arm 2: 975 mg acetaminophen and 600 mg ibuprofen every 6 hours for the first 48 hours to a maximum of 7 days;
  • Arm 3: 975 mg acetaminophen every 6 hours for the first 48 hours to a maximum of 7 days with a prescription for 6 tablets of 5 mg oxycodone every 6 hours as needed;
  • Arm 4: 975 mg acetaminophen and 600 mg ibuprofen every 6 hours for the first 48 hours to a maximum of 7 days with a prescription for 6 tablets of 5 mg oxycodone every 6 hours as needed.

Other than the differing pain regimens, all treatment and pre- and post-operative counselling will be standard of care at the discretion of the treating urologists. Participants will be contacted at 1 day and 7 days post-operatively to complete Brief Pain Inventory (BPI) questionnaires, assess how many tablets of oxycodone they have taken, and assess whether they would be comfortable returning to work. At post-operative visits, their treating urologist will assess them for the presence of hematoma. Comparisons will be made between study arms to assess for differences.

02

Conditions studied

  • Vasectomy
  • NSAIDs
  • Post-operative Care

Keywords

  • vasectomy
  • NSAIDs
  • Post-operative care
03

In context

Lead sponsor

Columbia University is the lead sponsor of 1,136 studies on the registry; 195 are open to participants now.

Of its 181 completed or terminated interventional studies of FDA-regulated products, 149 (82%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

- Consent for vasectomy

Exclusion criteria

Exclusion Criteria:

  • History of kidney or liver disease
  • History of chronic pain condition
  • History of drug abuse
05

Study design

Phase
Phase 1
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    Acetaminophen only

    Participants are encouraged to take only acetaminophen 975 mg every 6 hours for the first 48 hours to a maximum of 7 days after surgery.

    Drug: Acetaminophen

  • Experimental
    Acetaminophen + ibuprofen

    Participants are encouraged to take acetaminophen 975 mg and ibuprofen 600 mg every 6 hours for the first 48 hours to a maximum 7 days after surgery.

    Drug: Acetaminophen · Drug: ibuprofen

  • Experimental
    Acetaminophen + oxycodone

    Participants are encouraged to take acetaminophen 975 mg every 6 hours for the first 48 hours to a maximum of 7 days after surgery, and a prescription for 6 tablets of oxycodone 5 mg will be prescribed to take every 6 hours as needed for pain.

    Drug: Acetaminophen · Drug: oxycodone

  • Experimental
    Acetaminophen + ibuprofen + oxycodone

    Participants are encouraged to take acetaminophen 976 mg and ibuprofen 600 mg every 6 hours for the first 48 hours to a maximum of 7 days after surgery, and a prescription for 6 tablets of oxycodone 5 mg will be prescribed to take every 6 hours as needed for pain.

    Drug: Acetaminophen · Drug: ibuprofen · Drug: oxycodone

Interventions

  • Acetaminophen is a widely used, over-the-counter medication that relieves mild to moderate pain and reduces fever. Unlike NSAIDs like ibuprofen, it does not treat inflammation or swelling.

    Also known as: paracetamol, APAP

  • Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) used to relieve mild to moderate pain, reduce fever, and decrease inflammation.

    Also known as: Motrin

  • Oxycodone is a potent semi-synthetic opioid analgesic used to treat moderate to severe pain when other treatments are insufficient

    Also known as: Oxycodone Hydrochloride Capsules

06

What researchers measure

Primary outcomes

  1. Brief Pain Inventory (BPI) - Total Score

    The Brief Pain Inventory is a self-reported questionnaire to assess pain. Final scores will be averaged. The score range is 0 to 10, where a higher score indicates a worse outcome.

    Time frame: 1 to 7 days post operatively

Secondary outcomes

  1. Brief Pain Inventory (BPI) - Pain Interference Score

    The Pain Interference Score ranges from 0 to 10, where a higher score indicates greater interference with daily life.

    Time frame: 1 to 7 days post operatively

  2. Brief Pain Inventory (BPI) - Pain Severity Score

    The Pain Severity Score ranges from 0 to 10, where a higher score indicates greater severity.

    Time frame: 1 to 7 days post operatively

07

Study locations

2 of 2 sites recruiting
  • Columbia University Medical Center/ New York Presbyterian Hospital
    New York, New York 10032, United States
    Recruiting
  • New York-Presbyterian The One
    White Plains, New York 10604, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2026 (actual). Primary completion is estimated for Dec 2030, 51 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 6, 2026
First posted
Sep 17, 2026
StartActual
Sep 10, 2026
Primary completionEst.
Dec 31, 2030
CompletionEst.
Dec 31, 2035
Last update
Sep 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07824258
Responsible party
Aaron Brant (Assistant Professor of Urology, Columbia University) — Principal investigator
First posted
Sep 17, 2026
Start date
Sep 10, 2026
Primary completion
Dec 31, 2030 (estimated)
Completion
Dec 31, 2035 (estimated)
Last update
Sep 24, 2026

Study contacts

Aaron Brant, MD
Contact
menshealth@cumc.columbia.edu
212-305-0114
Aaron Brant, MD
principal investigator · Columbia University

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ibuprofen · Oxycodone

Start the discussion